title: The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells.
abstract: It is well known that some tumour cells are very resistant to chemotherapy-induced cell death which indicate poor prognosis for patients. Thus the aim of the present study was to investigate the effect of quercetin on pro-apoptotic activity of cisplatin in human cervix carcinoma cells (HeLa). Three variants of experiments were performed. In the first one cells were incubated with studied drugs separately for 8 and 24h. In the second, drugs were added to the culture medium simultaneously. In third cisplatin or quercetin addition was followed by subsequent quercetin or cisplatin treatment, respectively. We observed different apoptotic effects, dependent on the drug succession. Preincubation of cells with quercetin followed by cisplatin treatment appeared to be the most effective and was correlated with strong activation of caspase-3 and inhibition of both heat shock proteins (Hsp72) and multi-drug resistance proteins (MRP) levels. Our results indicate that quercetin pretreatment sensitizes HeLa cells to cisplatin-induced apoptosis in HeLa cells.
authors.affiliation: Department of Comparative Anatomy and Anthropology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland. jjgil@biotop.umcs.lublin.pl
authors.forename: J
authors.initials: J
authors.lastname: Jakubowicz-Gil
authors.forename: R
authors.initials: R
authors.lastname: Paduch
authors.forename: T
authors.initials: T
authors.lastname: Piersiak
authors.forename: K
authors.initials: K
authors.lastname: Głowniak
authors.forename: A
authors.initials: A
authors.lastname: Gawron
authors.forename: M
authors.initials: M
authors.lastname: Kandefer-Szerszeń
mesh_terms: D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001562:Benzimidazoles; D015153:Blotting, Western; D053148:Caspase 3; D020169:Caspases / Q000187:drug effects / Q000378:metabolism; D002945:Cisplatin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation / Q000187:drug effects; D019084:Fluorescent Antibody Technique, Indirect; D005456:Fluorescent Dyes; D006367:HeLa Cells; D006360:Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000187:drug effects; D006801:Humans; D009363:Neoplasm Proteins / Q000187:drug effects* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011794:Quercetin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D001562:Benzimidazoles; D005456:Fluorescent Dyes; D006360:Heat-Shock Proteins; D009363:Neoplasm Proteins; D011794:Quercetin; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases; C017807:bisbenzimide ethoxide trihydrochloride; D002945:Cisplatin